OrganaBio expanded autologous cell therapy logistics by opening a local PBMC isolation and cryopreservation site in San Diego. The facility is designed to isolate and cryopreserve PBMCs within three to four hours of collection, aiming to avoid quality degradation linked to shipping live material. OrganaBio says the San Diego workflow routinely achieves about 99.1% viability and recovery above 2.9 million cells per milliliter, attributing performance to rapid time-to-cryopreservation, standardized operating procedures, and a consistent quality system across sites. The move targets a known bottleneck for autologous immunotherapies, vaccines, and cell-based therapies where PBMCs serve as foundational starting material. For program operators, local processing can reduce manufacturing timeline risk and supply chain variability—two factors that often constrain patient access in autologous models.